Sugi Predict

Sugi Predict / Compounds / Lithium

Lithium

Lithium

SCHEMBL7180665

CCOc1ccc(PC(=O)c2c(C)cccc2C)c(OCC)c1.[Li]

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.45
▸ ALDH1A1 P00352 6/20 0.39
▸ SMN1; SMN2 Q16637 6/20 0.39
▸ NOTUM Q6P988 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ GAA P10253 2/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ LMNA P02545 3/20 0.38
▸ HPGD P15428 3/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ TSHR P16473 3/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180652 0.97 KDM4E (0.45) KDM4EALDH1A1SMN1; SMN2NOTUMMAPT
Lithium SCHEMBL7177249 0.92 KDM4E (0.40) KDM4EALDH1A1SMN1; SMN2NOTUMMAPT
Lithium SCHEMBL7182296 0.90 KDM4E (0.45) KDM4EALDH1A1SMN1; SMN2MAPTGAA
SCHEMBL7177244 0.89 KDM4E (0.40) KDM4EALDH1A1SMN1; SMN2NOTUMMAPT
Lithium SCHEMBL7179726 0.88 KMT2A (0.43) MAPTTDP1LMNAL3MBTL1KMT2A
Lithium SCHEMBL7188712 0.88 PPARG (0.43) TSHRTP53
Lithium SCHEMBL7178065 0.87 KDM4E (0.45) KDM4EALDH1A1SMN1; SMN2MAPTLMNA
SCHEMBL7182284 0.87 KDM4E (0.45) KDM4EALDH1A1SMN1; SMN2MAPTGAA
SCHEMBL7177209 0.87 SMN1; SMN2 (0.41) KDM4EALDH1A1SMN1; SMN2NOTUMMAPT
Lithium SCHEMBL7178017 0.86 KDM4E (0.42) KDM4EALDH1A1SMN1; SMN2MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KDM4E 3226/4885ALDH1A1 3416/4885SMN1; SMN2 2939/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KDM4E 2651/4885ALDH1A1 3984/4885SMN1; SMN2 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.